Our study suggests that the TRIM11 locus is a genetic modifier of PSP phenotype and potentially adds further evidence for the UPS having a key role in tau pathology, therefore representing a target for disease‐modifying therapies. The gene discussed is TRIM11; the disease is supranuclear palsy, progressive, 1.